Snapshot from Jun 10, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / Aldeyra Therapeutics securities class action
Regulatory securities lawsuit

Aldeyra Therapeutics securities class action

Analysis based on 19 articles · First reported May 18, 2026 · Last updated May 30, 2026

Sentiment
-70
Attention
4
Articles
19
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The rejection of Aldeyra Therapeutics's drug candidate by the United States — Food and Drug Administration caused a significant drop in Aldeyra Therapeutics's stock price. This event directly impacts investors who held shares of Aldeyra Therapeutics, leading to potential financial losses and a securities class action lawsuit.

pharmaceuticals legal services
Event Summary

Faruqi & Faruqi is investigating and has filed a federal securities class action lawsuit against Aldeyra Therapeutics, Inc. The lawsuit alleges that Aldeyra Therapeutics and its executives made false and misleading statements regarding the inconsistent results of their reproxalap clinical trials. On March 17, 2026, the United States — Food and Drug Administration issued a Complete Response Letter, rejecting Aldeyra Therapeutics's New Drug Application for reproxalap due to insufficient evidence of efficacy and inconsistent clinical study results. Following this news, Aldeyra Therapeutics's stock price plummeted by 70.7%, causing substantial losses for investors. Faruqi & Faruqi is encouraging affected investors to seek the role of lead plaintiff in the class action before the May 29, 2026 deadline.

Key Actions
100 Pomerantz LLP filed class action lawsuit Aldeyra Therapeutics
100 DJS Law Group reminded investors of Aldeyra Therapeutics
98 United States — Food and Drug Administration issued Complete Response Letter Aldeyra Therapeutics
90 Aldeyra Therapeutics misled investors
90 The Schall Law Firm reminded investors of lawsuit Aldeyra Therapeutics
81 Aldeyra Therapeutics announced success
80 Faruqi & Faruqi filed class action Aldeyra Therapeutics
Entities Involved
stock
Aldeyra Therapeutics
The stock price of Aldeyra Therapeutics fell significantly after the FDA rejected its drug candidate, leading to a securities class action lawsuit against the company for allegedly misleading investors.
Importance 100 Sentiment -90
priv
Faruqi & Faruqi
Faruqi & Faruqi is a law firm investigating and filing a securities class action lawsuit against Aldeyra Therapeutics on behalf of investors who suffered losses.
Importance 80 Sentiment 50
priv
The Schall Law Firm
The Schall Law Firm is initiating and representing investors in the class action lawsuit against Aldeyra Therapeutics, aiming to recover losses for shareholders.
Importance 80 Sentiment 60
priv
Pomerantz LLP
Pomerantz LLP is the law firm that filed the class action lawsuit against Aldeyra Therapeutics, representing investors who suffered losses.
Importance 80 Sentiment 20
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration issued a Complete Response Letter rejecting Aldeyra Therapeutics's New Drug Application for reproxalap, citing insufficient evidence of efficacy.
Importance 70 Sentiment 0
priv
DJS Law Group
DJS Law Group is one of the law firms reminding investors of the class action lawsuit against Aldeyra Therapeutics and encouraging shareholders to participate.
Importance 70 Sentiment 20
oth
Reproxalap
Reproxalap is an investigational drug candidate by Aldeyra Therapeutics for dry eye disease, which failed to receive United States — Food and Drug Administration approval, leading to the company's stock decline and the class action lawsuit.
Importance 60 Sentiment -80
per
Brian Schall
Brian Schall is an attorney at The Schall Law Firm and is actively involved in encouraging investors to join the class action lawsuit against Aldeyra Therapeutics.
Importance 40 Sentiment 50
per
Josh Wilson
Josh Wilson is a partner at Faruqi & Faruqi who is encouraging investors to contact him regarding the Aldeyra Therapeutics class action.
Importance 30 Sentiment 0
per
James Wilson
James Wilson, a partner at Faruqi & Faruqi, is encouraging investors who suffered losses in Aldeyra Therapeutics to contact him.
Importance 30 Sentiment 10
govactor
United States — United States Securities and Exchange Commission
The United States — United States Securities and Exchange Commission's rules (Rule 10b-5) are cited as the basis for the alleged violations by Aldeyra Therapeutics, indicating the regulatory framework governing the lawsuit.
Importance 20 Sentiment 0
index
Nasdaq-100
Nasdaq-100 is the stock exchange where Aldeyra Therapeutics's shares are traded.
Importance 10 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.